EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multiplexed FRET-FLIM profiling of immune checkpoint interactions predicts response to atezolizumab in urothelial carcinoma

Laura Camacho, Cristina Cacho-Navas, Killian O’Sullivan, James Miles, Juan Gumuzio, Fernando Aguirre, Salvador Martín Algarra, Carlos Eduardo de Andrea, Peter J. Parker, Véronique Calleja

Cancer Immunology, Immunotherapy · 18.11.2026

DOI: 10.1007/s00262-026-04644-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 18.11.2026. Verfasst von Laura Camacho und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have shown great promise in treating bladder cancer and are now part of the standard treatment for advanced disease. However, many patients still fail to respond to treatment, and at present, many biomarkers are assessed but have yet shown only limited results. Therefore, with the advent of combination treatments and the increase in immune-related adverse event, the search for reliable predictive biomarkers is paramount. Using a multiplexed enhanced FRET-FLIM-based technique (QF-Pro), we quantified the interaction of PD-1/PD-L1, CTLA-4/CD80, and TIGIT/CD155 immune checkpoints in a pre-treatment TMA of 46 patients treated with atezolizumab. The association between higher PD-1/PD-L1 ICP interaction state and treatment efficacy was demonstrated in the male sample cohort, where it identified patients with better progression-free survival. Conversely, patients exhibiting higher CTLA-4/CD80 engagement had a worse response to atezolizumab. Remarkably, the dual assessment of patients with high PD-1/PD-L1 and low CTLA-4/CD80 allowed to identify the best responders. These results indicate that the monitoring of patients’ immune profile in urothelial carcinoma might be critical in identifying patients who may benefit from combination therapy.

Förderung

  • Ministerio de Ciencia e Innovación

Zitieren

APA

Camacho, L., Cacho-Navas, C., O’Sullivan, K., Miles, J., Gumuzio, J., Aguirre, F., Algarra, S. M., Andrea, C. E. D., Parker, P. J., & Calleja, V. (2026). Multiplexed FRET-FLIM profiling of immune checkpoint interactions predicts response to atezolizumab in urothelial carcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04644-0

Vancouver

Camacho L, Cacho-Navas C, O’Sullivan K, Miles J, Gumuzio J, Aguirre F, et al. Multiplexed FRET-FLIM profiling of immune checkpoint interactions predicts response to atezolizumab in urothelial carcinoma. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04644-0

BibTeX
@article{Camacho2026,
  author = {Camacho, Laura and Cacho-Navas, Cristina and O’Sullivan, Killian and Miles, James and Gumuzio, Juan and Aguirre, Fernando and Algarra, Salvador Martín and Andrea, Carlos Eduardo de and Parker, Peter J. and Calleja, Véronique},
  title = {Multiplexed FRET-FLIM profiling of immune checkpoint interactions predicts response to atezolizumab in urothelial carcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04644-0}
}
Kostenlos starten →